ACIP‡ recommends that a MenB vaccine series may be administered to healthy adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of MenB. The preferred age for MenB vaccination is 16 through 18 years. The decision to vaccinate should be made based on shared clinical decision-making.2
The Affordable Care Act mandates insurance coverage for all vaccinations administered in accordance with ACIP recommendations. Health care providers should contact their individual plan to determine specific coverage and reimbursement requirements and adoption timeframes.4 MenB vaccines are available through the Vaccines for Children program.3
ACIP recommends certain persons aged ≥10 years who are at increased risk for meningococcal disease should receive MenB vaccine. These persons include:
The American Academy of Pediatrics
MenB is uncommon, but potentially fatal, and early symptoms may seem like the flu6,7
*CDC=Centers for Disease Control and Prevention.
†If at increased risk of disease or based on discussion with patient's family.
‡ACIP=Advisory Committee on Immunization Practices.
§Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab (Soliris®, Alexion Pharmaceuticals, Inc).
Contact your Pfizer Representative or call a Vaccine Specialist at
• If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose1
TRUMENBA is the only MenB vaccine that demonstrated cross-coverage of diverse MenB strains1
Only TRUMENBA targets both subfamilies, A and B, of fHBP.1
Please see full Prescribing Information.